AI assistant
Sending…
MetaVia Inc. — Director's Dealing 2017
Aug 16, 2017
34919_dirs_2017-08-16_886b2aa9-8642-4367-b8e9-4716705531b3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Gemphire Therapeutics Inc. (GEMP)
CIK: 0001638287
Period of Report: 2017-08-14
Reporting Person: MATHIESEN JEFFREY S (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-08-14 | Common Stock | M | 3207 | $3.59 | Acquired | 14134 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-08-14 | Employee Stock Option (right to buy) | $3.59 | M | 3207 | Disposed | 2025-09-24 | Common Stock (3207) | Direct |
More from MetaVia Inc.
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 18
Interim / Quarterly Report
2026
May 14
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 11
Annual Report
2026
Apr 27
Proxy Solicitation & Information Statement
2026
Apr 27
Regulatory Filings
2026
Apr 10
Regulatory Filings
2026
Apr 7
Regulatory Filings
2026
Apr 3